NASDAQ: EQ - Equillium, Inc.

Rentabilité sur six mois: +2.06%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Equillium, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.

plus de détails
It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2018-10-11
ISIN US29446K1060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://equilliumbio.com
Цена ао 2.06
Changement de prix par jour: +9.98% (0.631)
Changement de prix par semaine: +14.14% (0.608)
Changement de prix par mois: -9.87% (0.77)
Changement de prix sur 3 mois: -16.61% (0.8322)
Changement de prix sur six mois: +2.06% (0.68)
Changement de prix par an: -3.61% (0.72)
Evolution du prix sur 3 ans: -84.16% (4.38)
Evolution du prix sur 5 ans: -78.45% (3.22)
Evolution des prix sur 10 ans: 0% (0.694)
Evolution des prix depuis le début de l'année: -16.39% (0.83)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0.6101 10
P/BV 0.9753 9
P/E 0 0
EV/EBITDA 0.0261 10
Total: 6.13

Efficacité

Nom Signification Grade
ROA, % -26.39 0
ROE, % -59.08 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0572 10
Total: 9.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 128.97 10
Rentabilité Ebitda, % -54.54 0
Rentabilité EPS, % -73.88 0
Total: 2
Plus de détails

Établissements Volume Partager, %
Decheng Capital Management III (Cayman), LLC 4447308 12.61
Decheng Capital LLC 4447308 12.61
Vanguard Group Inc 836930 2.37
Cota Capital Management, LLC 562278 1.59
Tang Capital Management, LLC 400000 1.13
JP Morgan Chase & Company 350031 0.99
Renaissance Technologies, LLC 347500 0.99
Geode Capital Management, LLC 172387 0.49
Commonwealth Equity Services, LLC 100000 0.28
Callan Capital LLC 99688 0.28

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares Micro-Cap ETF 0.0032 17.09 1.54048



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Daniel Mark Bradbury Executive Chairman 158k 1961 (64 année)
Mr. Bruce D. Steel C.F.A. Co-Founder, President, CEO & Director 779.87k 1966 (59 années)
Ms. Christine Zedelmayer M.B.A., P.M.P. Senior VP & COO 553.73k 1970 (55 années)
Dr. Stephen Connelly Ph.D. Chief Scientific Officer & Director 571.32k 1982 (43 année)
Mr. Jason A. Keyes Chief Financial Officer N/A 1971 (54 année)
Mr. Michael Moore Vice President of Investor Relations & Corporate Communications N/A
Dr. Matthew Ritter Ph.D. Senior Vice President of Corporate Development N/A
Mr. Joel M. Rothman Chief Development Officer N/A 1969 (56 années)
Penny Tom Senior VP of Finance & Principal Accounting Officer N/A

Adresse: United States, La Jolla. CA, 2223 Avenida De La Playa - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://equilliumbio.com